SCHEMBL2833609

SCHEMBL2833609

C=CCCCOC(=O)c1c(F)cccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.48
THRB P10828 1/20 0.43
ALDH1A1 P00352 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
MAPT P10636 2/20 0.39
ELANE P08246 1/20 0.39
NPC1 O15118 1/20 0.39
S1PR4 O95977 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
XBP1 P17861 1/20 0.39
S1PR1 P21453 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835126 0.90 KMT2A (0.50) KMT2ATHRBALDH1A1L3MBTL1KDM4E
SCHEMBL2834534 0.84 ALDH1A1 (0.39) KMT2AALDH1A1L3MBTL1TDP1POLB
SCHEMBL2834998 0.83 CYP3A4 (0.50) ALDH1A1L3MBTL1KDM4ETDP1NPC1
SCHEMBL2835102 0.81 NPC1 (0.46) KMT2AALDH1A1L3MBTL1CES2CES1
SCHEMBL2835314 0.80 ESR1 (0.51) ALDH1A1L3MBTL1SMN1; SMN2TDP1MAPT
SCHEMBL2830668 0.80 CYP3A4 (0.58) KMT2ATHRBALDH1A1L3MBTL1KDM4E
SCHEMBL2834449 0.80 ESR1 (0.42) KMT2AALDH1A1L3MBTL1TDP1CA1
SCHEMBL2705485 0.78 TDP1 (0.53) ALDH1A1L3MBTL1SMN1; SMN2TDP1NPC1
SCHEMBL30901588 0.77 CYP3A4 (0.62) ALDH1A1L3MBTL1KDM4ETDP1NPC1
SCHEMBL29220273 0.77 CYP3A4 (0.62) ALDH1A1L3MBTL1KDM4ETDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101595082-B Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES 2013-08-21 CN disclosed
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
CN-101595082-A Ester cpds, the nonaqueous electrolytic solution that uses this ester cpds and lithium secondary battery UBE INDUSTRIES (JP) 2009-12-02 CN disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 KMT2A 1023/4885THRB 3013/4885ALDH1A1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.